In vitro the presence of P-glycoprotein is associated with the possibility to reverse multidrug resistance (MDR) with compounds with different structural features (Bradley et al., 1988) . Although many such compounds have been described, only a few can be expected to be active at clinically achievable concentrations: quinidine (Tsuruo et al., 1984) , amiodarone (Chauffert et al., 1987) , bepridil and cyclosporin A (Slater et al., 1986; Twentyman, 1988) are examples. During our investigations on the in vitro effects of resistance modifiers on daunorubicin and vincristine accumulation in freshly obtained human tumour cells (Schuurhuis et al., 1989b) we found that Cremophor EL, which is a polyethoxylated castor oil used as a solubiliser, e.g. of vitamins and of the immunosuppressant drug cyclosporin A, had effects on drug accumulation similar to other resistance modifiers used. In order to study whether this effect of Cremophor EL was related to MDR, we investigated the effects of Cremophor EL on anthracycline accumulation and anthracycline and vincristine cytotoxicity in MDR and sensitive model cell lines and we compared the results with those obtained using cyclosporin A and verapamil. Both human squamous lung cancer cells (SW-1573 , Keizer et al., 1989 and human myeloma cells (8226, Dalton et al., 1986 (8226, Dalton et al., , 1989b were used. The latter ones are of special interest because of the increased in vivo sensitivity of myeloma to a regimen containing vincristine, doxorubicin and dexamethasone (the VAD regimen) when verapamil is used as a modifier (Dalton et al., 1989a) . Both types of MDR cells overexpress P-glycoprotein (Dalton et al., 1989b; Kuiper et al., 1990) .
Cells were cultured in Dulbecco's modified minimal essential medium supplemented with 10% fetal bovine serum (Gibco, Paisley, Scotland) . The human multiple myeloma 8226Dox4 and 8226Dox40 cells were cultured in the presence of 40 and 400 nM doxorubicin (Adriablastina, Farmitalia, Milan, Italy) respectively. SW-1573/2R160 cells were derived from SW-1573/2R50 cells (Keizer et al., 1989; (Durie & Dalton, 1988; further reviewed in Twentyman, 1988 and Kaye, 1988 (Specia, Paris, France) . After two washes with ice-cold phosphate-buffered saline, the cells were transferred to liquid scintillation fluid. No corrections were made for direct binding of anthracyclines to the cells since binding was the same whether or not modifiers were present and was too low to affect the conclusions (5-20% at maximum). For efflux experiments sensitive cells were incubated with 0.5 lSM doxorubicin or daunorubicin. Resistant cells were incubated with 2.5 JAM daunorubcin (SW-i 573/2R 160) or 1 JiM doxorubicin (8226Dox4); this resulted in about the same intracellular drug amounts as in the sensitive cells in these experiments after 2 h of incubation. After washing with ice-cold Dulbecco's medium, the cells were resuspended in fresh ice-cold medium and incubated for 1 h at 37°C. After washing the cellassociated radioactivity was determined.
In Table I it is shown that Cremophor EL (132figml-') partly reversed doxorubicin resistance in SW-1573/2R160 cells (the dose modifying factor, DMF, was 6.3; resistance index = 77) while only a small effect was observed on the parent cell line. With concentrations higher than 132 fig ml-I higher dose modifying factors were found (> 10). At a concentration of 33 lg ml-' Cremophor EL had a small although significant effect in SW-1573/2R160 cells (DMF = 1.9, see Table I ). Two JAM pure cyclosporin A had a DMF of 8.3 ± 1.5 (mean ± s.d. in three experiments, P<0.01), while 2 JM cyclosporin A (Sandimmune), which Correspondence: G.J. Schuurhuis. Received 8 January 1990; and in revised form 17 April 1990. creasing its retention in the MDR cells (Table II) , as seems to be the case for cyclosporin A (Nooter et al., 1989 Figure 2 ). Two gM verapamil, a concentration which is ony achievable clinically with serious side-effects (Benson et al., 1985; Ozols et al., 1987) was less effective than Cremophor EL at a concentration of 33 yg ml-' (see Figure 2) .
One major determinant of the efficacy of a drug in the clinic can be its ability to bind to proteins (Koch-Weser & Sellers, 1976) . We have shown previously that an increase in the protein concentration signifcantly decreased the potency of resistance modifiers such as verapamil, bepridil, diltiazem and Ro 11-2933/001 to stimulate anthracycline accumulation in MDR cells . Table III Tables I and III) . At this protein concentration the dose modifying factors of verapamil, even at a concentration of 16I1M, are somewhat lower than for Cremophor EL (Table   III) . In addition, when 8226Dox4 cells were incubated in fresh human plasma for 2 h with doxorubicin and Cremophor EL (132 pg ml-'), followed by a 2 h postincubation in plasma with Cremophor EL only, the effect was about the same as in control experiments using 10% fetal bovine serum in the same incubation protocol (DMF of 2.5-3.5). These results indicate that proteins probably do not strongly interfere with the capacity of Cremophor EL to modulate MDR.
Despite the many studies addressing the mechanism of action of resistance modifiers, the answers offered are not yet satisfactory. Resistance modifiers seem to act at least partly by binding to P-glycoprotein (Safa et al., 1986; Cornwell et al., 1986; Foxwell et al., 1989) and competing for drug efflux via P-glycoprotein (Bradley et al., 1988) , thereby increasing drug accumulation in the cell. As an alterntive some resistance modifiers may act via their detergent effect on mem-1001- *---*, CEL (1329fg ml ').
branes as reported for Tween 80 (Carlsen et al., 1976 (Slater et al., 1986; Schuurhuis et al., 1989a ; this study).
Since protein kinase C (PKC) activity has been associated with MDR and its reversal (Aquino et al., 1988; Fine et al., 1988; O'Brien et al., 1989; Ferguson & Cheng, 1987) , it is of interest that Cremophor EL, like other resistance modifiers such as verapamil, tamoxifen, cyclosporin A and phenothiazines (Mori et al., 1980; O'Brian et al., 1985; Walker et al., 1989; Schatzman et al., 1981) , strongly inhibits PKC activity at concentrations comparable to those used in this study (Zhao et al., 1989) .
In conclusion, our findings demonstrate that Cremophor EL is a potent modifier of MDR in human myeloma cells at protein concentrations which closely mimic the in vivo situation. Clinical studies in myeloma with Cremophor EL as a resistance modifier thus seem warranted. Further, Cremophor EL may turn out to be useful in the treatment of other P-glycoprotein-containing tumours in addition to myeloma since we have found that in vitro the compound was active on other P-glycoprotein-containing human MDR cancer cells like squamous lung cancer cells (this paper) and ovarian cancer cells (submitted) as well as intrinsically resistant Pglycoprotein-containing human colon cancer cells (submitted).
